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Methods: Analyses	 were	 performed	 in	 the	 Multiple	 Environmental	 and	 Genetic	































The	 first	 association	 between	 CETP	 and	 the	 risk	 of	 venous	




performed	 only	 in	 men,	 and	 had	 a	 small	 number	 of	 individuals	
with	 VT.	 In	 another	 recent	 study	 on	 the	 association	 between	
plasma	 CETP	 activity	 and	 coagulability,	 a	 negative	 correlation	
was	observed	between	plasma	CETP	activity	and	activated	par-









chr16:g.57000885A>G,	 and	 chr16:g.57010948G>T,	were	 identi-
fied	 and	were	 strongly	 associated	with	 serum	CETP	 concentra-
tions,	with	effect	sizes	ranging	from	0.32	to	0.12	μm/mL	changes	
in	 CETP	 concentrations	 for	 the	 addition	 of	 one	 risk	 allele.9 The 
newly	 identified	 SNPs	 shared	 moderate	 linkage	 disequilibrium	
(LD)	with	the	previously	used	CETP	variants	in	the	literature	(e.g.,	
TaqI	 B1/B2,	 Arg451Gln,	 and	 Ala373Pro).	 Altogether,	 the	 three	
SNPs	explained	some	16%	of	variation	in	the	CETP	concentration.	




In	 the	current	study,	we	aimed	 to	use	 the	 three	newly	 iden-
tified	 CETP	 SNPs	 as	 genetic	 instrumental	 variables	 to	 explore	
the	 associations	 between	 genetically	 determined	 CETP	 con-
centrations	 and	 (a)	 hemostatic	 factors,	 including	 procoagulant,	




2  | MATERIAL S AND METHODS
2.1 | Study population
The	MEGA	 study	 is	 a	 population-based	 case-control	 study	 with	
the	aim	of	studying	the	etiology	of	VT.	The	study	design	was	ap-
proved	by	the	Ethics	Committee	of	the	Leiden	University	Medical	
Center,	 the	Netherlands,	 and	written	 informed	 consent	was	 ob-
tained	from	all	participants.	From	March	1999	to	September	2004,	
4956	consecutive	patients	aged	between	18	and	70	years	 (>90%	
of	 European	 ancestry)	with	 an	 objectively	 confirmed	 first	 VT	 or	
pulmonary	 embolism	 (PE)	 event	 were	 recruited	 from	 six	 antico-
agulation	 clinics	 in	 the	Netherlands.11	 The	 control	 subjects	were	
recruited	 from	 two	 sources:	 partners	 of	 VT	 patients	 when	 they	






were	 collected	 for	DNA	 analysis.	 In	 total,	 approximately	 60%	of	
DNA	material	was	extracted	 from	blood	 samples,	 and	40%	 from	
buccal	swabs	(Figure	1).
For	 the	 analyses	on	 the	 associations	between	genetically	 deter-
mined	 CETP	 concentrations	 and	 hemostatic	 factors,	 the	 following	
participants	 were	 selected:	 controls	 with	 a	 blood	 sample	 available,	









•	 Genetically	 determined	 CETP	 concentration	 only	
showed	 a	 weak	 negative	 association	 to	 factor	 VII	
activity.
•	 No	association	was	found	with	a	higher	risk	of	a	first	VT.










factors	 in	the	MEGA	study	 is	available	elsewhere.12	 In	brief,	FII	
activity,	 FVII	 activity,	 FVIII	 activity,	 FX	 activity	 and	 FXI	 activ-
ity	were	measured	with	a	mechanical	clot	detection	method	on	








(Dako	 A/S).14	 Antithrombin	 activity	 and	 protein	 C	 levels	 were	
measured	with	a	chromogenic	assay	on	an	STA-R	coagulation	an-
alyzer,	according	to	the	manufacturer's	instructions	(Diagnostica	
Stago).15	 Total	 protein	 S	 levels	 were	 measured	 with	 an	 ELISA	
(Diagnostica	 Stago).	 Plasminogen	 activator	 inhibitor-1	 (PAI-1)	
antigen	 levels	 were	 measured	 with	 a	 Technozym	 PAI-1	 ELISA	
reagent	 kit	 (Kordia	 Life	 Sciences;	 Biopool),	 and	 D-dimer	 levels	
were	measured	with	the	HemosIL	D-dimer	assay	on	an	ACL	TOP	
700	 analyzer.16	 Clot	 lysis	 time	 (CLT)	 was	 derived	 from	 a	 clot	
lysis	turbidity	profile,	which	has	been	described	previously	with	
details.12	 Several	 fibrinolytic	 factors	 were	 measured	 in	 only	 a	
subsample	of	the	MEGA	study,	including	PAI-1,	tissue-type	plas-
minogen	activator,	plasminogen	and	antiplasmin	(α2-antiplasmin)	
concentrations,	 and	 thrombin-activatable	 fibrinolysis	 inhibitor	
activity.	 All	 of	 the	 laboratory	 measurements	 were	 performed	
without	 knowledge	 of	 VT	 case-control	 status.	 The	 measure-
ments	of	PAI-1,	D-dimer	and	CLT	were	logarithm-transformed	to	
obtain	normal	distributions.










–1: bad blood quality
–60: history of
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(case = 3953/control = 4765)
5114 with DNA from blood
samples
(case = 2233/control = 2882)
3601 with DNA from buccal
swabs
(case = 1717/control = 1884)
(case = 3950/control = 4765)
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DNA sample unavailable
bad DNA quality
–41 (case = 17/control = 24):
–3 (case = 3/control = 0):
–436
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2.3 | SNP genotyping and genetic risk score












SNP	effect	 size	 into	account,	 the	weighted	GRS	was	calculated	as	
the	sum	of	numbers	of	CETP	concentration-increasing	alleles	mul-





with	95%	confidence	 intervals	 (CIs)	for	the	associations	of	both	 in-
dividual	SNPs	and	the	derived	CETP	GRSs	 (both	weighted	and	un-





factor	 measures	 per	 unit	 (μg/mL)	 of	 genetically	 determined	 CETP	
concentration.	 For	 this	 analysis,	 extreme	measures	 of	 each	 of	 the	
22	hemostatic	factors	were	excluded,	i.e.,	when	the	individual	value	
was	beyond	five	standard	deviations	from	the	mean.	To	correct	for	
TA B L E  1  Baseline	characteristics
Characteristics
Association with hemostatic factors in controls 
with blood samples (n = 2813)
A first VT event
Cases (n = 3950)
Controls 
(n = 4765)
Age	(y),	median	(IQR) 49	(39-58) 49	(38-58) 49	(39-58)
Women,	n	(%) 1490	(53) 2161	(54.7) 2536	(53.2)
BMI	(kg/m2),	median	(IQR) 25.1	(22.7-27.7) 26.3	(23.7-29.3) 25.1	(22.8-27.8)
DVT,	n	(%) NA 2316	(58.6) NA
PE,	n	(%) NA 1263	(32.0) NA
DVT	and	PE,	n	(%) NA 371	(9.4) NA
A	first	unprovoked	VT,	n	(%) NA 1149	(29.1)a  NA




Triglycerides	(mmol/L),	median	(IQR) 1.3	(1.0-1.9) 1.4	(1.0-1.9) 1.3	(1.0-1.9)
HDL-C	(mmol/L)	median	(IQR) 1.3	(1.1-1.6) 1.3	(1.0-1.5) 1.3	(1.1-1.6)
LDL-C	(mmol/L),	median	(IQR) 3.5	(2.9-4.2) 3.5	(2.9-4.2) 3.5	(2.9-4.2)
rs247616_C
Call	rate	(%) 98.4 79.5 83.4
Minor	allele	frequency	(%) 32.3 27.8 27.1
HWE	P value 0.78 NA 0.67
rs12720922_A
Call	rate	(%) 99.3 92.6 95.3
Minor	allele	frequency	(%) 16.7 15.8 15.3
HWE	P value 0.49 NA 0.074
rs1968905_G
Call	rate	(%) 99.5 92.5 95.6
Minor	allele	frequency	(%) 19.9 17.5 17.5
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multiple	 testing,	 the	 significance	 level	was	 set	 to	P < 0.0083; the 
standard	 significance	 level	 (P	 =	 0.05)	 was	 divided	 by	 the	 number	
(N	=	6)	of	principal	components	that	explain	over	95%	of	the	varia-
tion	of	22	hemostatic	factors.	To	identify	the	associations	between	




In	 addition	 to	 the	 analysis	 on	 the	 total	 population,	 a	 strati-
fied	analysis	was	performed	for	men	and	women.	The	risk	of	VT	
associated	with	genetically	determined	CETP	concentrations	was	









TA B L E  2  The	association	of	cholesteryl	ester	transfer	protein	(CETP)	concentration	genetic	risk	scores	(GRSs)	with	coagulation	factors	as	
determined	with	additive	models
Unweighted GRS Weighted GRS
N β 95% CI N β 95% CI
Anticoagulant	factors
Protein	C	activity	(IU/dL) 2753 −0.30 −0.99	to	0.39 2753 −1.31 −3.63	to	1.00
Total	protein	S	antigen	(IU/
dL)
2753 0.17 −0.46	to	0.80 2753 0.69 −1.42	to	2.80
Free	protein	S	(%) 2725 0.63 −0.054	to	1.32 2725 1.66 −0.66	to	3.97
TFPI	activity	(U/mL) 2752 −0.0060 −0.020	to	0.0090 2752 −0.019 −0.069	to	0.031
Antithrombin	activity	(IU/
dL)
2750 −0.12 −0.47	to	0.24 2750 −0.55 −1.75	to	0.65
Procoagulant	factors
Fibrinogen	activity	(g/L) 2748 0.0050 −0.015	to	0.026 2748 0.020 −0.049	to	0.089
Factor	II	activity	(IU/dL) 2751 −0.019 −0.48	to	0.44 2751 −0.17 −1.71	to	1.37
Factor	V	antigen	(U/mL) 2749 0.0020 −0.0040	to	0.0070 2749 0.0020 −0.016	to	0.020
Factor	VII	activity	(IU/dL) 2753 −0.92 −1.71	to	−0.13 2753 −3.08 −5.73	to	−0.42
Factor	VIII	activity	(IU/dL) 2750 1.00 −0.19	to	2.19 2750 4.26 0.26-8.26
Von	Willebrand	factor	anti-
gen	(IU/dL)
2747 0.72 −0.62	to	2.07 2747 2.99 −1.53	to	7.51
Factor	IX	antigen	(IU/dL) 2752 −0.053 −0.65	to	0.55 2752 −0.29 −2.31	to	1.74
Factor	X	activity	(IU/dL) 2752 0.12 −0.50	to	0.74 2752 0.13 −1.96	to	2.23
Factor	XI	activity	(IU/dL) 2752 0.061 −0.56	to	0.68 2752 0.24 −1.85	to	2.33
Global	assay	measurements
Clot	lysis	time	(min)a 2747 0.40 −0.30	to	1.21 2747 1.21 −1.29	to	3.87
ELPLT	(nM.min) 2741 −0.30 −4.50	to	3.90 2741 −1.43 −15.57	to	12.70
Fibrinolytic	factors
PAI-1	(ng/mL)a 704 0.90 −3.82	to	5.76 704 5.97 −9.79	to	24.61
t-PA	(ng/mL) 704 0.057 −0.086	to	0.20 704 0.38 −0.10	to	0.86
D-dimer	(ng/mL)a 2749 0.40 −1.69	to	2.43 2749 1.41 −5.26	to	8.55
Plasminogen	concentra-
tion	(%)
702 −0.18 −1.22	to	0.86 702 −0.90 −4.38	to	2.58
α2-Antiplasmin	concentra-
tion	(%)
702 0.056 −0.65	to	0.76 702 −0.11 −2.46	to	2.24
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found	with	 the	uncorrected	 significance	 level	 (P	 <	0.05),	 between	
rs247616:C>T	and	FVIII	activity	 (β	=	2.34	 IU/dL	per	μg/mL	geneti-
cally	 determined	CETP	 concentration,	 95%	CI	 0.37-4.32),	 and	 be-
tween	rs12720922:A>G	and	CLT	(β	=	1.71%	per	μg/mL	genetically	
determined	CETP	concentration,	95%	CI	0.20%-3.36%)	(Table	S1).
With	 the	GRSs	based	on	 the	 three	CETP	SNPs,	only	weak	as-
sociations	were	present	(Table	2):	FVII	activity	showed	associations	



































































Number of risk alleles
2 3 4 5 6
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2 3 4 5 6
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with	both	the	weighted	CETP	GRS	(β	=	−3.08	IU/dL	per	μg/mL	ge-
netically	 determined	CETP	 concentration,	 95%	CI	 −5.73	 to	 −0.42)	
and	the	unweighted	CETP	GRS	(β	=	−0.92	IU/dL	per	μg/mL	geneti-
cally	determined	CETP	concentration,	95%	CI	−1.71	to	−0.13).	FVIII	
activity	 also	 showed	 an	 association	with	 the	weighted	CETP	GRS	
(β	=	4.26	IU/dL	per	μg/mL	genetically	determined	CETP	concentra-
tion,	95%	CI	0.26-8.26).
For	 each	 participant,	 the	 number	 of	 CETP	 concentration-in-
creasing	(risk)	alleles	was	counted.	The	number	of	risk	alleles	ranged	
from	zero	to	six	(Figure	2),	and	similar	proportions	of	VT	cases	and	
controls	 fell	 into	 each	 allele	 count	 category.	 In	 logistic	 regression	
models,	neither	single	SNPs	(Table	S2)	nor	weighted	and	unweighted	
CETP	GRSs	(Table	3)	were	associated	with	an	increased	risk	of	a	first	
VT,	with	an	OR	of	0.98	 (95%	CI	0.85-1.13)	 for	 the	weighted	CETP	
GRS	in	the	entire	study	population	(Table	3).	No	associations	were	
observed	 in	 separate	 analyses	 on	 provoked	 and	 unprovoked	 VT;	
that	is,	ORs	were	1.01	(95%	CI	0.86-1.19)	for	provoked	VT	and	0.87	
(95%	CI	0.69-1.10)	for	unprovoked	VT	by	the	weighted	CETP	GRS,	





concentration	was	 found	 to	be	weakly	associated	with	FVII	 activ-
ity	 levels,	and	this	was	predominantly	attributable	 to	a	single	SNP	






composed	 of	 98	male	 participants,6	 but	 this	was	 not	 observed	 in	
the	current	study.	In	this	study,	the	frequency	of	the	TaqI	B2	allele	
was	 lower	 in	 VT	 cases	 than	 in	 controls	 (0.33	 vs	 0.47).	 Pecheniuk	
et	al	 further	 investigated	 the	allele	 frequencies	of	 two	other	non- 
synonymous	 CETP	 SNPs	 (Ala373Pro	 and	 Arg451Gln)	 in	 the	 same	
case-control	 study	 population.	 For	 both	 variants,	 CETP-increasing	
alleles	were	more	often	found	in	male	VT	cases	than	in	controls.23 
On	 the	 basis	 of	 this	 evidence,	 the	 authors	 suggested	 that	 CETP 
















A	 previous	 study	 showed	 inverse	 correlations	 of	 endogenous	
plasma	CETP	antigen	levels	with	prothrombin	time	induced	by	tissue	
factor	 (reflecting	 the	 extrinsic	 coagulation	 pathways)	 and	 with	 ac-
tivated	 FIX-induced	 clotting	 time	 (reflecting	 the	 intrinsic	 pathways),	






TA B L E  3  The	association	of	cholesteryl	ester	transfer	protein	concentration	genetic	risk	scores	(GRS)	with	the	first	venous	thrombosis	
(VT)	event	as	determined	with	additive	models
Unweighted GRS Weighted GRS
Ncase Ncontrol OR 95% CI Ncase Ncontrol OR 95% CI
All	participants 3101 3906 0.99 0.95-1.03 3101 3906 0.98 0.85-1.13
Participants	stratified	by	sex
Men	only 1406 1853 1.02 0.96-1.08 1406 1853 1.09 0.89-1.35
Women	only 1695 2053 0.98 0.92-1.03 1695 2053 0.91 0.74-1.11
Provoked/unprovoked	VT
Provoked	VT	only 2130 3906 1.01 0.96-1.06 2130 3906 1.01 0.86-1.19
Unprovoked	VT	only 902 3906 0.95 0.89-1.02 902 3906 0.87 0.69-1.10
PE/DVT
PE	and	DVT 309 3906 1.03 0.93-1.14 309 3906 1.04 0.73-1.49
DVT only 1804 3906 0.99 0.94-1.04 1804 3906 0.97 0.82-1.15
PE	only 988 3906 0.98 0.92-1.05 988 3906 0.96 0.78-1.19
Abbreviations:	CI,	confidence	interval;	DVT,	deep	vein	thrombosis;	OR,	odds	ratio;	PE,	pulmonary	embolism.









ings	 have	 indicated	 associations	 between	 FVII	 and	 lipid	 profiles29; 
however,	 the	FVII	 level	 is	not	a	risk	factor	for	VT	 in	the	 literature.22 






















edged.	First,	although	 it	 is	well	powered	for	the	main	analysis,	 the	
sample	size	might	still	be	insufficient	for	the	sex-stratified	analysis	








In	 conclusion,	 genetically	 determined	 CETP	 concentrations	
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